How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

879 results for

Actinic Keratoses

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01836367 Recruitment Status : Completed First Posted : April 19, 2013 Last Update Posted : December 31, 2013 Sponsor: Icahn School

2013 Clinical Trials

122. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. (Abstract)

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. Imiquimod 3.75% and 2.5% creams were studied for the treatment of actinic keratosis (AK) of the full face or balding scalp, to determine comparable efficacy and tolerability to imiquimod 5% cream.In two identical multicenter, randomized, double-blind, placebo controlled studies. Adult subjects with 5 to 20 visible lesions, or palpable AKs in an area

2013 Journal of drugs in dermatology : JDD Controlled trial quality: predicted high

123. Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: a randomized, comparative, prospective study. (Abstract)

Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: a randomized, comparative, prospective study. Photodynamic therapy (PDT) with methyl aminolevulinate (MAL) is effective for treating multiple actinic keratoses (AKs). Ablative fractional laser (FL) creates vertical channels that may facilitate MAL delivery and improve PDT response.To evaluate the efficacy of FL-assisted PDT (FL-PDT) in treating facial AKs in Korean patients.A prospective randomized non

2013 Journal of the European Academy of Dermatology and Venereology : JEADV Controlled trial quality: uncertain

124. Topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid: Randomized controlled trial with six months follow-up. (Abstract)

Topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid: Randomized controlled trial with six months follow-up. Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) is an effective treatment for actinic keratosis (AK) with some transient adverse events.The purpose of the study was to evaluate the efficacy and side effects of two different light doses when treating AKs with ALA-PDT on the face/scalp.Thirty-eight patients with two histologically confirmed AKs were

2013 Journal of Dermatological Treatment Controlled trial quality: uncertain

125. Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. (Abstract)

Pain during topical photodynamic therapy of actinic keratoses with 5-aminolevulinic acid and red light source: randomized controlled trial. Pain is the major drawback of photodynamic therapy (PDT), an otherwise effective treatment for actinic keratoses (AKs).To determine pain intensity and its dependence upon various factors during PDT with 5-aminolevulinic acid for face/scalp AKs.A prospective, randomized, within-patient comparison study was performed. Thirty-eight patients with at least two

2013 Photodermatology, photoimmunology & photomedicine Controlled trial quality: uncertain

126. Intensified fractional CO2 laser-assisted photodynamic therapy versus laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: A randomized half-side comparative trial on dorsal hands. (Abstract)

Intensified fractional CO2 laser-assisted photodynamic therapy versus laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: A randomized half-side comparative trial on dorsal hands. Photodynamic therapy (PDT) is a well-documented treatment for actinic keratosis (AK), but achieves inferior efficacy in organ transplant recipients (OTRs), particularly in acral regions. Ablative fractional laser (AFXL) intensifies the PDT response and may improve

2013 The British journal of dermatology Controlled trial quality: uncertain

127. An Investigator-initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses on Dorsal Hands and Forearms. Full Text available with Trip Pro

An Investigator-initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses on Dorsal Hands and Forearms. To evaluate the efficacy of combination cryotherapy and imiquimod 3.75% cream versus cryotherapy alone in the treatment of hypertrophic actinic keratosis on the dorsal hand and forearm.Twenty subjects with at least three hypertrophic actinic keratoses on each dorsal hand or forearm underwent (...) cryotherapy treatment to hypertrophic actinic keratoses. Following cryotherapy, subjects were randomized to have either their right or left dorsal hand or forearm treated with imiquimod 3.75% cream to begin on the same day as cryotherapy treatment. Subjects then utilized the two weeks on, two weeks off, two weeks on regimen of imiquimod 3.75% cream application. Local skin reactions were also assessed.For the cryotherapy/imiquimod 3.75% arm, the median total hypertrophic actinic keratosis reduction

2013 The Journal of clinical and aesthetic dermatology Controlled trial quality: uncertain

128. Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. Full Text available with Trip Pro

Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients. The risk of developing cutaneous squamous cell carcinoma (SCC) is markedly increased in organ transplant recipients (OTRs) compared to the normal population. Next to sun exposure, the immunosuppressive regimen is an important risk factor for the development of SCC in OTRs. Various gene mutations (e.g. TP53) and genetic alterations (e.g. loss of CDKN2A, amplification of RAS) have (...) been found in SCCs. The aim of this genome-wide study was to identify pathways and genomic alterations that are consistently involved in the formation of SCCs and their precursor lesions, actinic keratoses (AKs).To perform the analysis in an isogenic background, RNA and DNA were isolated from SCC, AK and normal (unexposed) epidermis (NS) from each of 13 OTRs. Samples were subjected to genome-wide expression analysis and genome SNP analysis using Illumina's HumanWG-6 BeadChips and Infinium II

2013 BMC Cancer

129. Conventional versus daylight photodynamic therapy for actinic keratosis: A randomized and prospective study in China. (Abstract)

Conventional versus daylight photodynamic therapy for actinic keratosis: A randomized and prospective study in China. Conventional photodynamic therapy (C-PDT) is an effective treatment for actinic keratoses (AKs) in Asia, with some unmet needs. Severe PDT-associated pain results in low treatment willingness. Daylight photodynamic therapy (DL-PDT) is a more simple and tolerable treatment that has the same efficacy as C-PDT in Europe. However, few studies have been conducted with Asian

2018 Photodiagnosis and Photodynamic Therapy Controlled trial quality: uncertain

130. Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice Full Text available with Trip Pro

Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice Actinic keratoses (AKs) are epidermal cutaneous neoplasia observed predominantly in middle-aged and older subjects with mainly photo type I and photo type II on sun-exposed surfaces as a result of DNA damage. AKs have historically been characterized as being "precancerous"; however, now it is considered by many authors a carcinoma in situ that can persist or progress to invasive

2018 Therapeutics and clinical risk management

131. Efficacy Endpoints in Clinical Trials in Actinic Keratosis Full Text available with Trip Pro

Efficacy Endpoints in Clinical Trials in Actinic Keratosis Actinic keratosis is regarded as a chronic disease of the skin and, although fluctuating, is chronically progressive. Approval of new products for the treatment of actinic keratosis requires the use of a standard methodology in clinical trials which emphasize complete clearance of all actinic keratoses in a treatment field in a defined time span and the evaluation of long-term efficacy in terms of recurrence rate among completely (...) cleared patients.Analysis of data from six previously published clinical trials in patients with actinic keratosis.There was poor agreement over a period of 1 month in the complete clearance endpoint. This variation in assessment renders recurrence in cleared patients invalid as the estimate of long-term efficacy. Furthermore, complete clearance was shown to depend heavily on the number of baseline actinic keratoses.The main endpoints presently in use for the assessment of short- and long-term

2018 Dermatology and therapy

132. Successful Treatment of Actinic Keratosis with Kanuka Honey Full Text available with Trip Pro

Successful Treatment of Actinic Keratosis with Kanuka Honey Actinic keratoses form as rough, scaly plaques on sun-exposed areas; they can be an important step in premalignant progression to squamous cell cancer of the skin. Currently, pharmacological treatments consist of topical immunomodulatory agents with poor side effect profiles. Use of honey has been common in both ancient and modern medicine, where it is now a key therapy in the management of wound healing. In vitro studies show the New (...) Zealand native Kanuka honey to have immunomodulatory and antimitotic effects, with recent evidence suggesting efficacy of topical application in a variety of dermatological contexts, including rosacea and psoriasis. Here, we present a case report of a 66-year-old gentleman with an actinic keratosis on his hand, which had been present for years. Regular application of Kanuka honey over three months resulted in remission immediately following the treatment period with no signs of recurrence at nine

2018 Case reports in dermatological medicine

133. Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. (Abstract)

Photodynamic therapy corrects abnormal cancer-associated gene expression observed in actinic keratosis lesions and induces a remodeling effect in photodamaged skin. Actinic keratoses (AK) are proliferations of neoplastic keratinocytes in the epidermis resulting from cumulative exposure to ultraviolet radiation (UVR), which are liable to transform into squamous cell carcinoma (SCC). Organ Transplant Recipients (OTR) have an increased risk of developing SCC as a consequence of long-term

2018 Journal of dermatological science

134. Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention

First Posted : August 22, 2018 Last Update Posted : March 19, 2019 See Sponsor: Shanghai Dermatology Hospital Collaborators: Huadong Hospital Peking University First Hospital The First Affiliated Hospital of Kunming Medical College General Hospital of Ningxia Medical University Chinese Academy of Medical Sciences Information provided by (Responsible Party): Xiuli Wang, Shanghai Dermatology Hospital Study Details Study Description Go to Brief Summary: Background Actinic keratoses (AKs) are often (...) /treatment Phase Actinic Keratoses Drug: ALA Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 300 participants Allocation: Randomized Intervention Model: Sequential Assignment Masking: Single (Outcomes Assessor) Primary Purpose: Prevention Official Title: Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter

2018 Clinical Trials

135. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review. (Abstract)

Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review. Actinic keratoses (AKs) are atypical, precancerous proliferations of keratinocytes that develop because of chronic exposure to ultraviolet (UV) radiation. Treatment of AK can be lesion-directed or field-directed. Field cancerization theory postulates that the skin surrounding AK is also at increased risk for possible malignant transformation since it has been exposed to the same chronic UV light. Field

2018 American journal of clinical dermatology

136. Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis lesions on the face or balding scalp. Condition or disease Intervention/treatment Phase Actinic Keratoses Drug: KX2-391 Ointment 1% Phase 1 Detailed Description: This study will be a open-label, single center, pharmacokinetic, and safety study of KX2-391 Ointment administered topically to the face or balding scalp of subjects with actinic keratosis. The study consists of Screening (...) Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies

2018 Clinical Trials

137. The Study of Plum-blossom Needling Enhancing Efficacy of Aminolevulinic Acid-photodynamic Therapy for Actinic Keratosis

; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only. During the next 1 year period of follow up, patients were clinically evaluated for new AKs. Condition or disease Intervention/treatment Phase Actinic Keratoses Device: PBN Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 250 participants Allocation: Randomized Intervention Model: Single Group Assignment Masking: Single (Outcomes Assessor (...) ALA cream and irradiation only. No Intervention: ALA-PDT Group The ALA-PDT group received ALA cream and irradiation only. Outcome Measures Go to Primary Outcome Measures : The clearance rate of Actinic Keratoses [ Time Frame: two weeks after first session ] The change rate in lesion clearance of Actinic Keratoses at two weeks after the first session will be measured as the primary outcome Secondary Outcome Measures : Treatment sessions [ Time Frame: two weeks after the last session ] Number

2018 Clinical Trials

138. 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities

. KG Information provided by (Responsible Party): photonamic GmbH & Co. KG Study Details Study Description Go to Brief Summary: This study evaluates the potential usefulness of photodynamic therapy with PD P 506 A in patients with actinic keratosis on the upper extremities for the first time. Condition or disease Intervention/treatment Phase Actinic Keratoses Drug: PD P 506 A Phase 2 Detailed Description: Patients will receive a second PD P 506 A-PDT on all AK lesions 1-2 weeks after the first PDT (...) 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 5-ALA Patch-PDT of Actinic

2018 Clinical Trials

139. Physician-Patient Communication and Patient-Reported Outcomes in the Actinic Keratosis TReatment-Adherence INitiative (AK-TRAIN): A Multicenter, Prospective, Real-Life study of Treatment Satisfaction, Quality of Life and Adherence to topical field-directe Full Text available with Trip Pro

Physician-Patient Communication and Patient-Reported Outcomes in the Actinic Keratosis TReatment-Adherence INitiative (AK-TRAIN): A Multicenter, Prospective, Real-Life study of Treatment Satisfaction, Quality of Life and Adherence to topical field-directe Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treatments challenge patients' adherence due to out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective

2018 Journal of the European Academy of Dermatology and Venereology

140. Efficacy and safety of daylight photodynamic therapy after tailored pretreatment with ablative fractional laser or microdermabrasion: a randomized, side-by-side, single-blind trial in patients with actinic keratosis and large area field cancerization. (Abstract)

Efficacy and safety of daylight photodynamic therapy after tailored pretreatment with ablative fractional laser or microdermabrasion: a randomized, side-by-side, single-blind trial in patients with actinic keratosis and large area field cancerization. Physical pretreatments can potentiate the efficacy of daylight photodynamic therapy (dPDT), but clinical comparative studies remain limited.Performed in large skin areas with actinic keratoses (AKs) and photodamage, this blinded, randomized

2018 British Journal of Dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>